Deciphera Pharmaceuticals
Latest round
- Series C
Last raised
- Jun 2017
Total raised
- $142M
Investors
- 5
About Deciphera Pharmaceuticals
Founded in 2003 by founder Daniel L. Flynn and based in Waltham, US, Deciphera Pharmaceuticals, LLC engages in the research, development, and commercialization of medicines and advanced kinase inhibitor treatments for cancer patients, targeting the tumor cell and the tumor microenvironment., Ltd.60 per share. The acquisition is expected to be completed in the third quarter of 2024, subject to customary closing conditions. Deciphera's product portfolio primarily consists of kinase inhibitors designed to target specific enzymes involved in cancer cell growth and survival. The company's product, QINLOCK (ripretinib), is approved for the treatment of advanced gastrointestinal stromal tumors (GIST) and is a potent inhibitor of a broad spectrum of KIT and PDGFRa mutations. Another product in Deciphera's pipeline is Vimseltinib, a CSF1R inhibitor for the treatment of tenosynovial giant cell tumour (TGCT). Additionally, Deciphera is developing DCC-3116, a ULK kinase inhibitor, to target autophagy, a process that cancer cells use to survive under stress conditions. The firm's pipeline also includes several other preclinical candidates, such as DCC-3084, a pan-RAF inhibitor in phase 1/2 trials, targeting solid tumors and hematologic malignancies. DCC-3009: A pan-KIT inhibitor in the IND-enabling stage, focusing on GIST. ISR Program: Research-stage development involving a GCN2 activator for the treatment of solid tumors.
Who invested in Deciphera Pharmaceuticals
5 investors across 3 rounds
See all investors in Deciphera Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Deciphera Pharmaceuticals
Who invested in Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Deciphera Pharmaceuticals raised?
Deciphera Pharmaceuticals has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Deciphera Pharmaceuticals last raise money?
Deciphera Pharmaceuticals's most recent round on record is a Series C, in Jun 2017.
What does Deciphera Pharmaceuticals do?
Founded in 2003 by founder Daniel L.
Where is Deciphera Pharmaceuticals headquartered?
Deciphera Pharmaceuticals is headquartered in Waltham, US.
Which VCs invest in companies like Deciphera Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Deciphera Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Deciphera Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.